{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:57:38Z","timestamp":1791313058817,"version":"4.3.1"},"reference-count":107,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2008,7,10]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Immunotherapy has a long history with striking but limited success in patients with melanoma. To date, interleukin-2 and interferon-alfa2b are the only approved immunotherapeutic agents for melanoma in the United States.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Tumor evasion of host immune responses, and strategies for overcoming tumor-induced immunosuppression are reviewed. Several novel immunotherapies currently in worldwide phase III clinical testing for melanoma are discussed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The limitations of immunotherapy for melanoma stem from tumor-induced mechanisms of immune evasion that render the host tolerant of tumor antigens. For example, melanoma inhibits the maturation of antigen-presenting cells, preventing full T-cell activation and downregulating the effector antitumor immune response. New immunotherapies targeting critical regulatory elements of the immune system may overcome tolerance and promote a more effective antitumor immune response. These include monoclonal antibodies that block the cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and toll-like receptor 9 (TLR9) agonists. Blockade of CTLA4 prevents inhibitory signals that downregulate T-cell activation. TLR9 agonists stimulate dendritic cell maturation and ultimately induce a more effective immune response. These approaches have been shown to stimulate acute immune activation with concomitant appearance of transient adverse events mediated by the immune system. The pattern and duration of immune responses associated with these new modalities differ from those associated with cytokines and cytotoxic agents. In addition, vaccines are being developed that may ultimately target melanoma either alone or in combination with these immunomodulatory therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The successes of cytokine and interferon therapy of melanoma, coupled with an array of new approaches, are generating new enthusiasm for the immunotherapy of melanoma.<\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2007.14.6423","type":"journal-article","created":{"date-parts":[[2008,7,9]],"date-time":"2008-07-09T05:16:18Z","timestamp":1215580578000},"page":"3445-3455","source":"Crossref","is-referenced-by-count":194,"title":["Next Generation of Immunotherapy for Melanoma"],"prefix":"10.1200","volume":"26","author":[{"given":"John M.","family":"Kirkwood","sequence":"first","affiliation":[{"name":"From the University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA; and the First Department of Internal Medicine, University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad A.","family":"Tarhini","sequence":"additional","affiliation":[{"name":"From the University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA; and the First Department of Internal Medicine, University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica C.","family":"Panelli","sequence":"additional","affiliation":[{"name":"From the University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA; and the First Department of Internal Medicine, University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stergios J.","family":"Moschos","sequence":"additional","affiliation":[{"name":"From the University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA; and the First Department of Internal Medicine, University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassane M.","family":"Zarour","sequence":"additional","affiliation":[{"name":"From the University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA; and the First Department of Internal Medicine, University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa H.","family":"Butterfield","sequence":"additional","affiliation":[{"name":"From the University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA; and the First Department of Internal Medicine, University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen J.","family":"Gogas","sequence":"additional","affiliation":[{"name":"From the University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA; and the First Department of Internal Medicine, University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1177\/107327480200900104"},{"key":"R2","unstructured":"Atkins MB, Kunkel L, Sznol M, et al: High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update. Cancer J Sci Am 6:S11,2000-S14, (suppl 1)"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2105"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.4.477"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.10.1650"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510360033032"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1994.1963"},{"key":"R8","unstructured":"Nauts HC, Fowler GA, Bogatko FH: A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man: A critical analysis of 30 inoperable cases treated by Coley's mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med Scand 276:1,1953-103, (suppl)"},{"key":"R9","unstructured":"Nathanson L: Spontaneous regression of malignant melanoma: A review of the literature on incidence, clinical features, and possible mechanisms. Natl Cancer Inst Monogr 44:67,1976-76,"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1084\/jem.155.6.1823"},{"key":"R11","unstructured":"Mazumder A, Grimm EA, Zhang HZ, et al: Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins. Cancer Res 42:913,1982-918,"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Strausser JL, Mazumder A, Grimm EA, et al: Lysis of human solid tumors by autologous cells sensitized in vitro to alloantigens. J Immunol 127:266,1981-271,","DOI":"10.4049\/jimmunol.127.1.266"},{"key":"R13","unstructured":"Kirkwood JM, Ernstoff M: Melanoma: Therapeutic options with recombinant interferons. Semin Oncol 12:7,1985-12,"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-1-32"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.37464"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.7"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.12.2444"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.9.2370"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.03.052"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1038\/302305a0"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1126\/science.3131876"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1177\/106002809102500509"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Bruton JK, Koeller JM: Recombinant interleukin-2. Pharmacotherapy 14:635,1994-656,","DOI":"10.1002\/j.1875-9114.1994.tb04156.x"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198806163182401"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197812)42:6<2613::AID-CNCR2820420617>3.0.CO;2-K"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Key ME, Brandhorst JS, Hanna MG Jr: Synergistic effects of active specific immunotherapy and chemotherapy in guinea pigs with disseminated cancer. J Immunol 130:2987,1983-2992,","DOI":"10.4049\/jimmunol.130.6.2987"},{"key":"R27","unstructured":"Peters LC, Brandhorst JS, Hanna MG Jr: Preparation of immunotherapeutic autologous tumor cell vaccines from solid tumors. Cancer Res 39:1353,1979-1360,"},{"key":"R28","unstructured":"Motl SE: Technology evaluation: Canvaxin, John Wayne Cancer Institute\/CancerVax. Curr Opin Mol Ther 6:104,2004-111,"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1038\/nm0398-328"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2013.04.009"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1669"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1988.tb00234.x"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2001.1040s1001.x"},{"key":"R36","unstructured":"Mitchell MS: Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 25:623,1998-635,"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200203000-00001"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.90140.707"},{"key":"R39","unstructured":"Banchereau J, Palucka AK, Dhodapkar M, et al: Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61:6451,2001-6458,"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-005-0106-6"},{"key":"R41","unstructured":"Butterfield LH, Ribas A, Dissette VB, et al: Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9:998,2003-1008,"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200409000-00004"},{"key":"R43","unstructured":"Ribas A, Butterfield LH, McBride WH, et al: Genetic immunization for the melanoma antigen MART-1\/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res 57:2865,1997-2869,"},{"key":"R43A","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31816a8910"},{"key":"R44","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20012142"},{"key":"R45","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5"},{"key":"R46","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1996.420"},{"key":"R47","unstructured":"Mihm MC Jr, Clemente CG, Cascinelli N: Tumor infiltrating lymphocytes in lymph node melanoma metastases: A histopathologic prognostic indicator and an expression of local immune response. Lab Invest 74:43,1996-47,"},{"key":"R48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.2498"},{"key":"R49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.15.3477"},{"key":"R50","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199601000-00009"},{"key":"R51","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700545"},{"key":"R52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053007"},{"key":"R53","doi-asserted-by":"crossref","unstructured":"Bouwhuis M, Suciu S, Kruit W, et al: Prognostic value of autoantibodies (auto-AB) in melanoma patients (pts) in the EORTC 18952 trial of adjuvant interferon (IFN) compared to observation (obs). J Clin Oncol 25:118s,2007, (abstr 8507)","DOI":"10.1200\/jco.2007.25.18_suppl.8507"},{"key":"R54","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M511525200"},{"key":"R55","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.3.1462"},{"key":"R56","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200306000-00005"},{"key":"R57","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(04)01429-9"},{"key":"R58","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2004.07.017"},{"key":"R59","unstructured":"Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Bio l3:65,1992-71,"},{"key":"R60","doi-asserted-by":"publisher","DOI":"10.4161\/cc.5.16.3018"},{"key":"R61","unstructured":"Sun K, Wang L, Zhang Y: Dendritic cell as therapeutic vaccines against tumors and its role in therapy for hepatocellular carcinoma. Cell Mol Immuno l3:197,2006-203,"},{"key":"R62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.109"},{"key":"R63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.205"},{"key":"R64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0600651103"},{"key":"R65","unstructured":"Schreiber RD: Cancer vaccines 2004 opening address: The molecular and cellular basis of cancer immunosurveillance and immunoediting. Cancer Immun 5:1,2005, (suppl 1)"},{"key":"R66","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.4.2391"},{"key":"R67","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.12.5809"},{"key":"R68","doi-asserted-by":"crossref","unstructured":"Sharma S, Stolina M, Lin Y, et al: T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J Immunol 163:5020,1999-5028,","DOI":"10.4049\/jimmunol.163.9.5020"},{"key":"R69","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.4.2071"},{"key":"R70","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.3.1257"},{"key":"R71","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.6.863"},{"key":"R72","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.20.100301.064842"},{"key":"R73","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2059"},{"key":"R74","doi-asserted-by":"publisher","DOI":"10.1038\/328267a0"},{"key":"R75","doi-asserted-by":"crossref","unstructured":"Khattri R, Auger JA, Griffin MD, et al: Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses. J Immunol 162:5784,1999-5791,","DOI":"10.4049\/jimmunol.162.10.5784"},{"key":"R76","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90125-6"},{"key":"R77","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5238.985"},{"key":"R78","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.2.459"},{"key":"R79","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2005.03.536"},{"key":"R80","doi-asserted-by":"crossref","unstructured":"Alegre ML, Shiels H, Thompson CB, et al: Expression and function of CTLA-4 in Th1 and Th2 cells. J Immunol 161:3347,1998-3356,","DOI":"10.4049\/jimmunol.161.7.3347"},{"key":"R81","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1711.1999.00795.x"},{"key":"R82","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00259-X"},{"key":"R83","doi-asserted-by":"publisher","DOI":"10.1038\/ni0702-611"},{"key":"R84","unstructured":"Hurwitz AA, Foster BA, Kwon ED, et al: Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60:2444,2000-2448,"},{"key":"R85","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.26.15074"},{"key":"R86","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.3.355"},{"key":"R87","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.6.3401"},{"key":"R88","doi-asserted-by":"publisher","DOI":"10.1007\/s002620100181"},{"key":"R89","doi-asserted-by":"crossref","unstructured":"Ribas A, Antonia S, Sosman J, et al: Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma. J Clin Oncol 25:118s,2007, (suppl; abstract 3000)","DOI":"10.1200\/jco.2007.25.18_suppl.3000"},{"key":"R90","doi-asserted-by":"crossref","unstructured":"Bulanhagui C, Ribas A, Pavlov D, et al: Phase I clinical trials of CP-675,206: Tumor responses are sufficient but not necessary for prolonged survival. J Clin Oncol 24:461s,2006, (suppl; abstr 8036)","DOI":"10.1200\/jco.2006.24.18_suppl.8036"},{"key":"R91","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2177"},{"key":"R93","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2318"},{"key":"R94","doi-asserted-by":"crossref","unstructured":"Hamid O, Urba WJ, Yellin M, et al: Kinetics of response to ipilimumab (MDX-010) in patients with stage III\/IV melanoma. J Clin Oncol 25:478s,2007, (suppl; abstr 8525)","DOI":"10.1200\/jco.2007.25.18_suppl.8525"},{"key":"R95","doi-asserted-by":"crossref","unstructured":"Weber JS, Hersh EM, Yellin M, et al: The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma [poster]. J Clin Oncol 25:477s,2007, (suppl; abstr 8523)","DOI":"10.1200\/jco.2007.25.18_suppl.8523"},{"key":"R97","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9129"},{"key":"R98","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099153"},{"key":"R99","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.14_suppl.580"},{"key":"R100","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.102"},{"key":"R101","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000211304.60126.8f"},{"key":"R102","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2006.08.002"},{"key":"R103","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6346(02)00269-3"},{"key":"R104","doi-asserted-by":"crossref","unstructured":"Brand OJ, Lowe CE, Heward JM, et al: Association of the interleukin-2 receptor alpha (IL-2Ralpha)\/CD25 gene region with Graves' disease using a multilocus test and tag SNPs. Clin Endocrinol (Oxf) 66:508,2007-512,","DOI":"10.1111\/j.1365-2265.2007.02762.x"},{"key":"R105","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2005.00249.x"},{"key":"R106","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.24.021605.090535"},{"key":"R107","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.6.3631"},{"key":"R108","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200737034"},{"key":"R109","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2006.04727.x"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2007.14.6423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T05:23:25Z","timestamp":1709097805000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2007.14.6423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,10]]},"references-count":107,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2008,7,10]]}},"alternative-id":["10.1200\/JCO.2007.14.6423"],"URL":"https:\/\/doi.org\/10.1200\/jco.2007.14.6423","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,10]]}}}